Literature DB >> 8831150

Characterization of a beta-Asp33 isoform of recombinant hirudin sequence variant 1 by low-energy collision-induced dissociation.

P Schindler1, D Müller, W Märki, H Grossenbacher, W J Richter.   

Abstract

A new low-concentration congener (Ib) of recombinant hirudin sequence variation 1 was structurally characterized as a beta-Asp33 isoform of the parent protein (Ia). alpha-beta Isomerization at the 33-position was expected in view of the previous isolation of a potential precursor (Asp33-Gly34-anhydro-hirudin (Ic)), i.e., a succinimide-type dehydration product liable to undergo facile hydrolysis with ring opening, yielding beta- (along with alpha-) aspartates. In order to identify and locate the modified site in Ib, a sufficiently small peptide ([28-35]-octapeptide IIIb) was prepared by disulfide bond reduction, S-alkylation (pyridylethylation) and twofold enzymatic degradation (Glu-C protease followed by trypsin). When [M + H] + ions of IIIb were analyzed by electrospray ionization tandem mass spectrometry (ESIMS/MS) and low-energy collision-induced dissociation (CID), a singular [bn + H2O]+ ion indicative of beta-Asp in the neighboring 'n + 1' position was observed for n = 5. This located the beta-Asp residue unambiguously in the 6-position of IIIb and thus, as expected, in the 33-position of Ib. The formation of this highly diagnostic [bn + H2O]+ ion, for which precedents had only been reported for CID under high-energy conditions, requires net OH migration from one to another amino acid position. Confirmatory results from 18O-labeling of the suspected migratory oxygen atom (beta-Asp33-CO18OH) together with the low-energy genesis suggest a specific charge-triggered rather than charge-remote mechanism for the formation of the ion. The analogy of this process to the ejection of the C-terminal amino acid similarly involving net OH rearrangement is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831150     DOI: 10.1002/(SICI)1096-9888(199609)31:9<967::AID-JMS381>3.0.CO;2-K

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  8 in total

1.  Quantitating the relative abundance of isoaspartyl residues in deamidated proteins by electron capture dissociation.

Authors:  Jason J Cournoyer; Cheng Lin; Michael J Bowman; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2006-09-25       Impact factor: 3.109

2.  Analysis of isoaspartate in peptides by electrospray tandem mass spectrometry.

Authors:  W D Lehmann; A Schlosser; G Erben; R Pipkorn; D Bossemeyer; V Kinzel
Journal:  Protein Sci       Date:  2000-11       Impact factor: 6.725

3.  Deamidation: Differentiation of aspartyl from isoaspartyl products in peptides by electron capture dissociation.

Authors:  Jason J Cournoyer; Jason L Pittman; Vera B Ivleva; Eric Fallows; Lucy Waskell; Catherine E Costello; Peter B O'Connor
Journal:  Protein Sci       Date:  2005-02       Impact factor: 6.725

4.  Inhibition of succinimide formation in aqueous Zn-rHirudin suspensions.

Authors:  U Gietz; T Arvinte; R Alder; H P Merkle
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

5.  Electron transfer dissociation with supplemental activation to differentiate aspartic and isoaspartic residues in doubly charged peptide cations.

Authors:  Wai Yi Kelly Chan; T W Dominic Chan; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2010-02-08       Impact factor: 3.109

6.  Distinguishing Aspartic and Isoaspartic Acids in Peptides by Several Mass Spectrometric Fragmentation Methods.

Authors:  Nick DeGraan-Weber; Jun Zhang; James P Reilly
Journal:  J Am Soc Mass Spectrom       Date:  2016-09-09       Impact factor: 3.109

7.  Chemical degradation kinetics of recombinant hirudin (HV1) in aqueous solution: effect of pH.

Authors:  U Gietz; R Alder; P Langguth; T Arvinte; H P Merkle
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

8.  Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures.

Authors:  Grace C Chu; Dirk Chelius; Gang Xiao; Hui K Khor; Sururat Coulibaly; Pavel V Bondarenko
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.